美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

AnaptysBio Inc

43.80

0.0000

成交量：- -

成交额：- -

市值：12.59亿

市盈率：-95.16

高：43.80

开：43.80

低：43.80

收：43.80

52周最高：49.76

52周最低：41.99

股本：2,874.83万

流通股本：2,874.83万

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-0.4603

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

AnaptysBio Inc

交易所：

NASDAQ

成立时间：

- -

员工人数：

- -

公司地址：

- -

官网：

http://www.anaptysbio.com

邮编：

- -

电话：

- -

传真：

- -

简介：

AnaptysBio, Inc.在特拉华成立于2005年11月。该公司是一家专注于为自身免疫性疾病和炎症性疾病提供创新免疫疗法的临床阶段生物技术公司。该公司的临床阶段研发管线包括rosnilimab，一种选择性致病性T细胞清除剂，已完成治疗中重度类风湿性关节炎（RA）的IIb期临床试验。此外，其研发管线还包括ANB033，一种CD122拮抗剂，目前正在进行治疗乳糜泻（CeD）和嗜酸性粒细胞性食管炎（EoE）的Ib期临床试验；以及ANB101，一种BDCA2调节剂，目前正在进行Ia期临床试验。AnaptysBio还通过财务合作发现了多种治疗性抗体，并将其授权给GSK，包括将PD-1拮抗剂Jemperli（dostarlimab-gxly）授权给GSK，将IL-36R拮抗剂（imsidolimab）授权给Vanda Pharmaceuticals Inc.。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/ANABV/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ANABV","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANABV\",,,,,undefined,":{"symbol":"ANABV","market":"US","secType":"STK","nameCN":"AnaptysBio Inc","latestPrice":43.8,"timestamp":1781294400000,"preClose":43.8,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":28748255,"shares":28748255,"eps":-0.46027142,"marketStatus":"休市中","change":0,"latestTime":"06-12 16:00:00 EDT","open":43.8,"high":43.8,"low":43.8,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.46027142,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1781510400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":43.8,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANABV\",,,,,undefined,":{"symbol":"ANABV","floatShares":28748255,"roa":"--","roe":"--","lyrEps":0,"shares":28748255,"dividePrice":0,"high":43.8,"amplitude":0,"preClose":43.8,"low":43.8,"week52Low":41.99,"pbRate":"--","week52High":49.755,"institutionHeld":0,"latestPrice":43.8,"eps":-0.46027142,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.46027142,"open":43.8,"prevYearClose":45.52,"prevWeekClose":43.8,"prevMonthClose":43.8,"prevQuarterClose":45.52,"fiveDayClose":43.8,"twentyDayClose":43.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ANABV\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-04-20","symbol":"ANABV","reason":null,"defaultRemindTime":1776691800000,"announcedDate":"2026-04-01","type":"delisting","dateTimestamp":1776657600000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ANABV\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ANABV\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3846,"buy":0.5385,"hold":0.0769,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5385,"analysts":13,"updateTime":1767758400000},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.anaptysbio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":-0.0378},{"period":"ytd","weight":-0.0378}],"compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.12},{"period":"6month","weight":0.088},{"period":"1year","weight":0.2286},{"period":"ytd","weight":0.0877}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"AnaptysBio, Inc.在特拉华成立于2005年11月。该公司是一家专注于为自身免疫性疾病和炎症性疾病提供创新免疫疗法的临床阶段生物技术公司。该公司的临床阶段研发管线包括rosnilimab，一种选择性致病性T细胞清除剂，已完成治疗中重度类风湿性关节炎（RA）的IIb期临床试验。此外，其研发管线还包括ANB033，一种CD122拮抗剂，目前正在进行治疗乳糜泻（CeD）和嗜酸性粒细胞性食管炎（EoE）的Ib期临床试验；以及ANB101，一种BDCA2调节剂，目前正在进行Ia期临床试验。AnaptysBio还通过财务合作发现了多种治疗性抗体，并将其授权给GSK，包括将PD-1拮抗剂Jemperli（dostarlimab-gxly）授权给GSK，将IL-36R拮抗剂（imsidolimab）授权给Vanda Pharmaceuticals Inc.。","exchange":"NASDAQ","name":"AnaptysBio Inc","nameEN":"AnaptysBio Inc"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"ANABV\",market:\"US\",,,undefined,":null}}